Literature DB >> 27116356

Determination of rivaroxaban, apixaban and edoxaban in rat plasma by UPLC-MS/MS method.

Wan-Li Zhang1, Dan Lou2, Dong-Tao Zhang3, Yin Zhang3, Huan-Jie Huang4.   

Abstract

To establish a rapid and sensitive ultra performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) method for the determination of rivaroxaban, apixaban and edoxaban in rat plasma. The analytes and the internal standard (diazepam) were separated on an Acquity UPLC BEH C18 chromatography column (2.1 mm × 50 mm, 1.7 μm) using gradient elution with a mobile phase of acetonitrile and 0.1 % formic acid in water at a flow rate of 0.4 mL/min. The detection was performed on a triple quadrupole tandem mass spectrometer by multiple reaction monitoring mode to monitor the precursor-to-product ion transitions of m/z 436.1 → 145.1 for rivaroxaban, m/z 460.0 → 443.1 for apixaban, m/z 548.2 → 366.1 for edoxaban and m/z 285.2 → 193.1 for diazepam (IS) using a positive electrospray ionization interface. The method was validated over a concentration range of 1.0-200 ng/mL for rivaroxaban, 1.0-100 ng/mL for apixaban and 1.0-500 ng/mL for edoxaban. Total time for each chromatograph was 3.5 min. The intra- and inter-day precision and accuracy of the quality control samples at low, medium, and high concentration levels exhibited relative standard deviations <10.5 % and the accuracy values ranged from -9.9 to 11.3 %. The method was successfully applied to a pharmacokinetic study of rivaroxaban, apixaban and edoxaban in rats.

Entities:  

Keywords:  Apixaban; Edoxaban; Pharmacokinetics; Plasma; Rivaroxaban; UPLC–MS/MS

Mesh:

Substances:

Year:  2016        PMID: 27116356     DOI: 10.1007/s11239-016-1367-y

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  21 in total

1.  Simultaneous determination of irbesartan and hydrochlorothiazide in human plasma by ultra high performance liquid chromatography tandem mass spectrometry and its application to a bioequivalence study.

Authors:  Xiangjun Qiu; Zhe Wang; Bing Wang; Hui Zhan; Xiaofeng Pan; Ren-ai Xu
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2014-03-13       Impact factor: 3.205

2.  A novel prothrombin time assay for assessing the anticoagulant activity of oral factor Xa inhibitors.

Authors:  Yu Chen Barrett; Zhaoqing Wang; Robert M Knabb
Journal:  Clin Appl Thromb Hemost       Date:  2012-04-02       Impact factor: 2.389

3.  Apixaban: first global approval.

Authors:  Julia Watson; Glen Whiteside; Caroline Perry
Journal:  Drugs       Date:  2011-10-22       Impact factor: 9.546

4.  Determination of dabigatran, rivaroxaban and apixaban by ultra-performance liquid chromatography - tandem mass spectrometry (UPLC-MS/MS) and coagulation assays for therapy monitoring of novel direct oral anticoagulants.

Authors:  E M H Schmitz; K Boonen; D J A van den Heuvel; J L J van Dongen; M W M Schellings; J M A Emmen; F van der Graaf; L Brunsveld; D van de Kerkhof
Journal:  J Thromb Haemost       Date:  2014-10       Impact factor: 5.824

5.  "Center punch" and "whole spot" bioanalysis of apixaban in human dried blood spot samples by UHPLC-MS/MS.

Authors:  Naiyu Zheng; Long Yuan; Qin C Ji; Heidi Mangus; Yan Song; Charles Frost; Jianing Zeng; Anne-Françoise Aubry; Mark E Arnold
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2015-02-21       Impact factor: 3.205

6.  Determination of rivaroxaban--a novel, oral, direct Factor Xa inhibitor--in human plasma by high-performance liquid chromatography-tandem mass spectrometry.

Authors:  G Rohde
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2008-07-23       Impact factor: 3.205

7.  Simultaneous determination of rivaroxaban and dabigatran levels in human plasma by high-performance liquid chromatography-tandem mass spectrometry.

Authors:  Marie Korostelev; Kevin Bihan; Lison Ferreol; Nadine Tissot; Jean-Sebastien Hulot; Christian Funck-Brentano; Noël Zahr
Journal:  J Pharm Biomed Anal       Date:  2014-08-15       Impact factor: 3.935

8.  Simultaneous determination of mangiferin and neomangiferin in rat plasma by UPLC-MS/MS and its application for pharmacokinetic study.

Authors:  Xiangjun Qiu; Jian-Long Zhao; Cong Hao; Canli Yuan; Nuan Tian; Zhi-Sheng Xu; Ruan-Min Zou
Journal:  J Pharm Biomed Anal       Date:  2016-02-26       Impact factor: 3.935

Review 9.  Review of atrial fibrillation outcome trials of oral anticoagulant and antiplatelet agents.

Authors:  Jean-Pierre Bassand
Journal:  Europace       Date:  2012-03       Impact factor: 5.214

Review 10.  Edoxaban: an update on the new oral direct factor Xa inhibitor.

Authors:  Henri Bounameaux; A John Camm
Journal:  Drugs       Date:  2014-07       Impact factor: 9.546

View more
  5 in total

1.  Amalgamation of solid dispersion and melt adsorption techniques for augmentation of oral bioavailability of novel anticoagulant rivaroxaban.

Authors:  Pranav J Shah; Milan P Patel; Jigar Shah; Anroop B Nair; Sabna Kotta; Bhavin Vyas
Journal:  Drug Deliv Transl Res       Date:  2022-04-25       Impact factor: 4.617

2.  Core shell stationary phase for a novel separation of some COVID-19 used drugs by UPLC-MS/MS Method: Study of grapefruit consumption impact on their pharmacokinetics in rats.

Authors:  Sally Tarek Mahmoud; Marwa A Moffid; Rawda M Sayed; Eman A Mostafa
Journal:  Microchem J       Date:  2022-07-15       Impact factor: 5.304

3.  Rivaroxaban versus nadroparin for preventing deep venous thrombosis after total hip arthroplasty following femoral neck fractures: A retrospective comparative study.

Authors:  Chi Zhang; Bo Xu; Guanzhao Liang; Xianshang Zeng; Chen Yang; Fan Zhang; Zi Wan; Weiguang Yu; Deng Chen; Zhe Ge; Xinchao Zhang
Journal:  J Int Med Res       Date:  2018-03-21       Impact factor: 1.671

4.  Quantification of apixaban in human plasma using ultra performance liquid chromatography coupled with tandem mass spectrometry.

Authors:  Hyeon-Cheol Jeong; Tae-Eun Kim; Kwang-Hee Shin
Journal:  Transl Clin Pharmacol       Date:  2019-03-27

5.  Rapid Assay for the Therapeutic Drug Monitoring of Edoxaban.

Authors:  Md Abdur Rashid; Saiqa Muneer; Yahya Alhamhoom; Nazrul Islam
Journal:  Biomolecules       Date:  2022-04-17
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.